What are the approved indications, recommended dosing, administration instructions, and safety precautions for Vraylar (cariprazine) in adult patients?

Vraylar (Cariprazine): FDA-Approved Indications, Dosing, and Safety

Vraylar (cariprazine) is FDA-approved for treating schizophrenia (adults and adolescents ≥13 years), acute manic/mixed episodes of bipolar I disorder (adults and children ≥10 years), bipolar depression (adults only), and as adjunctive therapy for major depressive disorder (adults only), with dosing ranging from 1.5-6 mg daily depending on indication and patient age. 1

FDA-Approved Indications

Vraylar has four distinct approved indications 1:

• Schizophrenia: Adults and pediatric patients ≥13 years
• Bipolar I Disorder (Manic/Mixed Episodes): Adults and pediatric patients ≥10 years
• Bipolar Depression: Adults only
• Major Depressive Disorder: Adjunctive to antidepressants in adults only

Dosing by Indication

Schizophrenia

Adults 1:

• Starting dose: 1.5 mg once daily
• Day 2: Can increase to 3 mg
• Recommended range: 1.5-6 mg daily
• Maximum: 6 mg daily
• Critical caveat: Doses above 6 mg provide no additional benefit but significantly increase adverse reactions

Adolescents (13-17 years) 1:

• Starting dose: 0.5 mg once daily
• Day 3: Increase to 1.5 mg
• Day 5: May increase to 3 mg
• Day 8: May increase to 4.5 mg
• Recommended range: 1.5-4.5 mg daily
• Maximum: 4.5 mg daily

Bipolar I Disorder (Manic/Mixed Episodes)

Adults 1:

• Starting dose: 1.5 mg once daily
• Day 2: Increase to 3 mg
• Recommended range: 3-6 mg daily
• Maximum: 6 mg daily

Children/Adolescents (10-17 years) 1:

• Starting dose: 0.5 mg once daily
• Day 3: Increase to 1.5 mg
• Day 5: Increase to 3 mg
• Day 8: May increase to 4.5 mg
• Recommended dose: 3 mg or 4.5 mg daily
• Maximum: 4.5 mg daily

Bipolar Depression (Adults Only)

1:

• Starting dose: 1.5 mg once daily
• Day 15: May increase to 3 mg based on response
• Maximum: 3 mg daily

Major Depressive Disorder - Adjunctive Therapy (Adults Only)

1:

• Starting dose: 1.5 mg once daily
• Day 15: May increase to 3 mg based on response
• Maximum: 3 mg daily
• Important: Titration intervals <14 days result in higher adverse reaction rates 1

Administration Instructions

• Once daily dosing with or without food 1
• No food restrictions simplify administration
• Available capsule strengths: 0.5 mg, 0.75 mg, 1.5 mg, 3 mg, 4.5 mg, and 6 mg 1

Critical Pharmacokinetic Considerations

Vraylar has an exceptionally long half-life due to its active metabolites (didesmethyl-cariprazine has a 1-3 week half-life), meaning dose changes take several weeks to reach steady state 1, 2, 3. This requires:

• Monitor patients for adverse reactions and treatment response for several weeks after starting or changing doses 1
• Metabolite accumulation occurs over 4-8 weeks 3
• This distinguishes cariprazine from other antipsychotics and demands patience in dose titration

Drug Interactions Requiring Dose Adjustment

Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)

When initiating Vraylar 1:

• Schizophrenia/Bipolar Mania/Bipolar Depression/MDD: Start 0.5 mg daily; increase to 0.75 mg if needed

When adding inhibitor to stable Vraylar dose 1:

• If on 1.5-3 mg: Reduce to 0.5 mg daily
• If on 4.5-6 mg: Reduce to 0.75 mg daily

Moderate CYP3A4 Inhibitors (e.g., erythromycin, diltiazem, fluconazole)

When initiating Vraylar 1:

• Start 0.75 mg daily; increase to 1.5 mg if needed

When adding inhibitor to stable Vraylar dose 1:

• If on 1.5-3 mg: Reduce to 0.75 mg daily
• If on 4.5-6 mg: Reduce to 1.5 mg daily

CYP3A4 Inducers

Concomitant use is NOT recommended 1 - avoid combining with rifampin, carbamazepine, phenytoin, St. John's Wort

Pediatric patients should NOT initiate Vraylar while taking strong or moderate CYP3A4 inhibitors 1

Boxed Warnings

1. Increased Mortality in Elderly with Dementia-Related Psychosis

Vraylar is NOT approved for dementia-related psychosis - elderly patients with dementia treated with antipsychotics have increased death risk 1

2. Suicidal Thoughts and Behaviors

Antidepressants (relevant for MDD indication) increase suicide risk in pediatric and young adult patients - closely monitor all patients for clinical worsening and emergence of suicidal ideation 1

Major Safety Precautions

Cerebrovascular Events

Increased stroke and TIA risk in elderly patients with dementia-related psychosis 1

Neuroleptic Malignant Syndrome (NMS)

Potentially fatal - immediately discontinue if suspected and provide intensive symptomatic treatment 1

Tardive Dyskinesia

Risk increases with duration of treatment and cumulative dose - consider discontinuation if signs develop 1

Metabolic Changes 1

Monitor for:

• Hyperglycemia/diabetes mellitus: Check fasting glucose and HbA1c
• Dyslipidemia: Monitor lipid panel
• Weight gain: Regular weight monitoring (though cariprazine shows relatively neutral metabolic profile compared to other antipsychotics 2, 4)

Hematologic Monitoring

In patients with pre-existing low WBC or history of drug-induced leukopenia/neutropenia, perform complete blood counts frequently during first months of therapy 1

Orthostatic Hypotension and Syncope

Monitor heart rate and blood pressure, especially in patients with cardiovascular/cerebrovascular disease or conditions predisposing to hypotension 1

Seizures

Use cautiously in patients with seizure history or conditions lowering seizure threshold 1

Cognitive and Motor Impairment

Caution patients about operating machinery or driving until they know how Vraylar affects them 1

Most Common Adverse Reactions

Based on clinical trials, adverse reactions occurring in ≥5% and at least twice placebo rate 1, 4:

Schizophrenia: Extrapyramidal symptoms, akathisia

Bipolar Mania: Extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, restlessness

Bipolar Depression: Nausea, akathisia, restlessness, extrapyramidal symptoms

MDD (Adjunctive): Akathisia, restlessness, fatigue, constipation, nausea, insomnia, increased appetite, dizziness, extrapyramidal symptoms

Key tolerability finding: Akathisia and extrapyramidal symptoms are dose-dependent, occurring in 9-19% depending on dose versus 4-8% with placebo 2, 4. These are generally mild-to-moderate and rarely cause discontinuation (4.3% overall) 4.

Special Populations

Pregnancy

Based on animal data, may cause fetal harm - use only if benefit justifies potential fetal risk 1

Lactation

Recent data shows cariprazine and metabolites are detectable in breast milk with cumulative relative infant dose of 2.54% (below standard 10% safety threshold), but two cases of infant lethargy were reported, one resolving with maternal dose reduction 5. The long half-life of didesmethyl-cariprazine raises concerns about metabolite accumulation in infants, particularly with higher maternal doses.

Hepatic/Renal Impairment

Do not use in severe hepatic or renal disease 6

Contraception

Females of childbearing age must use effective contraception during treatment 7

Clinical Pearls

• Unique D3-preferring pharmacology: Cariprazine has 10-fold higher affinity for D3 versus D2 receptors, distinguishing it from other antipsychotics 8, 9, 2
• Efficacy in negative symptoms: Shows superiority over risperidone for predominant negative symptoms in schizophrenia 2, 10
• Metabolically favorable: Weight gain typically <1 kg, neutral effects on glucose/lipids, no prolactin elevation, no QT prolongation 2, 4
• High completion rates: 90% study completion in MDD trials indicates good tolerability 4
• Patience required: Due to long half-life, allow several weeks between dose adjustments and when assessing efficacy 1, 3